Natural History of Hypereosinophilia and Hypereosinophilic Syndromes
COHESION
Study of Clinical Profiles of Patients Followed for Chronic Hypereosinophilia and/or Hypereosinophilic Syndrome by the Creation of a National Cohort
2 other identifiers
observational
600
1 country
1
Brief Summary
Unexplained chronic hypereosinophilia (HE) and hypereosinophilic syndromes (HES) are heterogeneous regarding the organ involvements (heart, lungs, skin, .. or none), the evolutionary profiles, the response to treatments. Underlying mechanisms are largely unknown and may associate genetic predisposing factors (germinal ? somatic?), environmental factors (alimentation, tobacco use, hormones, infections, ..) The COHESion study aims to study all clinical and biological characteristics of HE/HES patients and their evolutionary profiles, with a focus on genetic factors and the mechanisms supporting transitory or persistant chronic HE/HES (in absence of any well identified extrinsic trigger like drugs, parasitosis, ..)
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2019
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 6, 2019
CompletedFirst Submitted
Initial submission to the registry
May 15, 2019
CompletedFirst Posted
Study publicly available on registry
July 12, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 6, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 1, 2031
February 20, 2026
February 1, 2026
10 years
May 15, 2019
February 18, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Frequency of the different clinical manifestations at time of diagnosis and during follow-up of the hypereosinophilic syndrome (HES)
The primary objective of the study is to describe the frequency of the different clinical manifestations at diagnosis and during follow-up of the hypereosinophilic syndrome (HES/HE). The primary endpoint is the frequency of the different clinical manifestations and/or organs damage related to hypereosinophilia.
10 years
Secondary Outcomes (8)
Frequency of the evolutionary profiles
10 years
Frequency of complications depending of the type of HES
10 years
Frequency of organ damage profiles before and after 18 years old.
10 years
Frequency of clinical complications profiles before and after 18 years old.
10 years
Frequency of HLA alleles and variants / mutations on other genes of HE/HES
10 years
- +3 more secondary outcomes
Study Arms (1)
Eosinophilia/Hypereosinophilic syndrome
patient with eosinophilia and/or hypereosinophilic syndrome
Interventions
Additional blood samples for biobanking
Eligibility Criteria
Patients with Hypereosinophilia and Hypereosinophilic Syndromes
You may qualify if:
- Men or Women of any age :
- With the diagnosis criteria of hyperosinophlia OR hypereosinophilic syndrome OR specific organ eosinophilic disease according to the consensus conference of the International Cooperative Working Group on Eosinophil Disorders (ICOG-EO)
- With an AEC \> 1500/mm3 or organ damage related to the presence of eosinophils in the tissues or organs whatever the context (idiopathic, clonal or reactive, including drug-related, parasitic or allergic)
- HES diagnosis since 2005/01/01
- Patients socially insured
- Patient who agreed to participate to the study, its proceedings and duration.
You may not qualify if:
- Known HIV infection
- Not socially insured
- Person unable to receive a enlighten information
- Person who refuse to sign the consent
- Persons deprived of their liberty
- Persons benefiting from a system of legal protection (tutelage / guardianship)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hôpital Roger Salengro, CHU
Lille, France
Related Publications (1)
Lefevre G, Bleuse S, Puyade M, Moulis G, Neel A, Abisror N, Baudet A, Bonnotte B, Dion J, Dossier A, Grall M, Lifermann F, Limal N, Lioger B, Machelart I, Mohr C, Outh R, Queyrel-Moranne V, Slama B, Trefond L, Abou Chahla W, Ackerman F, Belfeki N, Berezne A, Blade JS, Bouderbala MA, Chebrek S, Cottin V, De Almeida S, De Masson A, Dezoteux F, Goulenok T, Jachiet V, Jouvray M, Latu I, Ledoult E, Leurs A, Lugosi M, Martin M, Melboucy-Belkhir S, Morati-Hafsaoui C, Quemeneur T, Rohmer J, Roy-Peaud F, Sanges S, Schleinitz N, Staumont-Salle D, Taille C, Terriou L, Tieulie N, Koenga JDE, Schwarb L, Panel K, Kahn JE, Groh M; COHESion study group. Hypereosinophilia and Hypereosinophilic Syndromes: First Findings From a Nationwide Multicenter Cohort. Allergy. 2025 Apr;80(4):1100-1110. doi: 10.1111/all.16463. Epub 2025 Jan 5.
PMID: 39757773RESULT
Biospecimen
Blood.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Guillaume Lefevre
University Hospital, Lille
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 15, 2019
First Posted
July 12, 2019
Study Start
May 6, 2019
Primary Completion (Estimated)
May 6, 2029
Study Completion (Estimated)
May 1, 2031
Last Updated
February 20, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share